AYTU BIOPHARMA, INC (NASDAQ: AYTU) reports roughly 10.1 million shares in its public float — the portion of outstanding stock available for trading. Behind that headline number sit 8.81 million pre-funded warrants priced at $0.0001, effectively free to convert. Those warrants nearly double the company's real supply of shares to approximately 18.9 million.
ShareStructure assigns a dilution risk grade of 4 out of 10 (MODERATE), reflecting the absence of toxic convertible debt, preferred stock, or an at-the-market facility, offset by the sheer scale of the warrant overhang.
The Pre-Funded Stack
Pre-funded warrants — instruments where the buyer has already paid nearly the full purchase price and can convert to common stock for a nominal penny — are held by three institutional investors: Nantahala Capital Management (12.1% holder with a board-designation right), Stonepine Capital Management (10.1%), and individual investor Laurence W. Lytton (5.6%). All three are classified as long-only holders, not short-term flippers.
The critical governor is a set of 19.99% ownership blockers — contractual caps that prevent any single holder from exceeding 19.99% of outstanding common stock upon exercise. As of March 2026, these blockers were amended so they cannot be overridden by shareholder vote. The blockers slow the pace at which shares enter the market. They do not reduce the total.
To put the scale in perspective: those 8.81 million pre-funded warrants represent roughly 81% of the company's 10.87 million shares outstanding.
Additional Warrant Layers
Beyond the pre-funded instruments, two other warrant tranches add conditional supply. Approximately 2.17 million Tranche A warrants carry a $1.59 exercise price. These warrants include a forced-exercise trigger — a clause that accelerates their expiration to 30 days if the stock closes at or above $3.18 for 40 consecutive trading sessions. That mechanism channels new supply directly into sustained strength.
Another 1.19 million warrants from August 2022 sit at a $2.32 strike. They expire around August 2027.
Authorized Headroom and Shelf
Aytu has 200 million shares authorized against 10.87 million outstanding, leaving ample room for future issuance. A $100 million universal shelf registration — a pre-filed SEC document that lets a company sell securities on short notice — is effective but unused. Because Aytu's public float market capitalization is below $75 million, the "baby shelf" rule caps issuance at roughly one-third of that value per twelve-month period, or about $8 million.
Historical Pattern
The company has executed six reverse splits since 2015, compounding to roughly 11.7 million-to-one cumulatively. Major equity raises or warrant events have landed in June in three consecutive years — 2023, 2024, and 2025. An 8-K was filed on June 25, 2026, whose contents have not yet been extracted.
Twelve-month dilution through new share issuance has been modest at 9.6%, mostly from pre-funded warrant exercises. No new capital raise has occurred since June 2025, and there are no convertible notes or preferred equity outstanding. The structural risk here is not ongoing toxic financing — it is the latent conversion of a warrant stack that is already economically issued and waiting behind a set of contractual gates.